

IFW

Docket No. 285327US0PCT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Yukihiko SAEKI, et al.

SERIAL NO: 10/566,253

FILED: January 30, 2006

FOR: METHOD OF INHIBITING PRODUCTION OF STEOPONTIN



GAU: 1615

EXAMINER:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon




Corwin P. Umbach, Ph.D.
Registration No. 40,211

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NAME OF APPLICANT:

Yukihiko SAEKI, et al.

SERIAL NO: 10/566,253

GROUP: 1615

FILED: January 30, 2006


EXAMINER:

FOR: METHOD OF INHIBITING PRODUCTION OF OSTEOPONTIN

STATEMENT OF RELEVANCY

All of the references on Form PTO-1449:

These references are cited in the present specification on pages 3 and 4.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 285327US0PCT		SERIAL NO. 10/566,253	
				APPLICANT Yukihiko SAEKI, et al.			
				FILING DATE January 30, 2006		GROUP 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AN						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AO	Kikuo ISODA, et al., "Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation", Circulation Research, JOURNAL OF THE AMERICAN HEART ASSOCIATION, http://www.circresaha.org , 91, 1, July 12, 2002, pages 77-82					
	AP	Stefan GAUER, et al., "Differential Regulation of Osteopontin Expression in the Clipped and Nonclipped Kidney of Two-Kidney, One-Clip Hypertensive Rats", American Journal of Hypertension, Ltd., vol. 16, no. 3, March 2003, pages 214-222					
	AQ	Yoshinobu KOGUCHI, et al., "High Plasma Osteopontin Level and Its Relationship with Interleukin-12-mediated Type 1 T Helper Cell Response in Tuberculosis", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 167, no. 10, May 15, 2003, pages 1355-1359					
	AR	Kayo MAEDA, et al., "Distinct Roles of Osteopontin Fragments in the Development of the Pulmonary Involvement in Sarcoidosis", Lung, vol. 179, no. 5, 2002, pages 279-291					
	AS	Rumiko KAWASHIMA, et al., "Expression of Osteopontin in Kupffer Cells and Hepatic Macrophages and Stellate Cells in Rat Liver after Carbon Tetrachloride Intoxication: A Possible Factor for Macrophage Migration into Hepatic Necrotic Areas", Biochemical and Biophysical Research Communications, vol. 256, no. 3, 1999, pages 527-531					
	AT	Deepak AGRAWAL, et al., "Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling", Journal of the National Cancer Institute, vol. 94, no. 7, April 3, 2002, pages 513-521					
	AU	Jae-Hoon KIM, MD, et al., "Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer", JAMA, www.jama.com , vol. 287, no. 13, April 3, 2002, pages 1671-1679					
	AV	George N. THALMANN, et al., "Osteopontin: Possible Role in Prostate Cancer Progression", Clinical Cancer Research, vol. 5, no. 8, August 1999, pages 2271-2277					
	AW	Hemant SINGHAL, et al., "Elevated Plasma Osteopontin in Metastatic Breast Cancer Associated with Increased Tumor Burden and Decreased Survival", Clinical Cancer Research, vol. 3, April 1997, pages 605-611					
	AX	Kenjiro KOHRI, et al., "Structure and Expression of the mRNA Encoding Urinary Stone Protein (Osteopontin)**", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 20, July 15, 1993, pages 15180-15184					
	AY	Yuko OYAMA, et al., "PPAR γ Ligand Inhibits Osteopontin Gene Expression Through Interference With Binding of Nuclear Factors to A/T-Rich Sequence in THP-1 Cells", Circulation Research, http://www.circresaha.org , 90, February 22, 2002, pages 348-355					
	AZ	Minoru TAKEMOTO, et al., "NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells", British Journal of Pharmacology, vol. 133, 2001, pages 83-88				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner						Date Considered	
<p>*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							